Now trading at a price of $26.43, PFIZER INC has moved 2.24% so far today.
Over the last year, PFIZER INC logged a 0.0% change, with its stock price reaching a high of $27.69 and a low of $20.92. Over the same period, the stock underperformed the S&P 500 index by -12.7%. AThe company's 50-day average price was $25.13. Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. Based in New York, NY, the Large-Cap Health Care company has 81,000 full time employees. PFIZER INC has offered a 6.4% dividend yield over the last 12 months.
Increasing Revenues but Narrowing Margins:
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Revenue (M) | $40,905 | $41,651 | $73,636 | $101,175 | $59,553 | $63,627 |
| Operating Margins | 28% | 17% | 33% | 34% | 2% | 13% |
| Net Margins | 39% | 22% | 30% | 31% | 4% | 13% |
| Net Income (M) | $16,026 | $9,159 | $21,979 | $31,372 | $2,119 | $8,031 |
| Net Interest Expense (M) | $1,573 | $1,449 | $1,291 | $1,238 | $2,209 | $3,091 |
| Depreciation & Amort. (M) | $5,755 | $4,681 | $5,191 | $1,519 | $6,290 | $7,013 |
| Diluted Shares (M) | 5,675 | 5,632 | 5,708 | 5,733 | 5,709 | 5,700 |
| Earnings Per Share | $2.82 | $1.63 | $3.85 | $5.47 | $0.37 | $1.41 |
| EPS Growth | n/a | -42.2% | 136.2% | 42.08% | -93.24% | 281.08% |
| Avg. Price | $32.65 | $31.35 | $39.42 | $49.3 | $28.79 | $26.43 |
| P/E Ratio | 11.34 | 19.0 | 10.06 | 8.82 | 75.76 | 18.61 |
| Free Cash Flow (M) | $10,542 | $12,177 | $29,869 | $26,031 | $4,793 | $9,835 |
| CAPEX (M) | $2,046 | $2,226 | $2,711 | $3,236 | $3,907 | $2,909 |
| EV / EBITDA | 13.6 | 15.26 | 8.69 | 8.63 | 31.41 | 15.06 |
| Total Debt (M) | $52,150 | $6,703 | $38,436 | $35,829 | $71,888 | $78,243 |
| Net Debt / EBITDA | 2.99 | 0.42 | 1.24 | 0.98 | 9.4 | 5.13 |
| Current Ratio | 0.88 | 1.35 | 1.4 | 1.22 | 0.91 | 1.17 |
Pfizer has weak operating margins with a negative growth trend, declining EPS growth, and a highly leveraged balance sheet. On the other hand, the company has growing revenues and increasing reinvestment in the business working in its favor. Furthermore, Pfizer has positive cash flows and just enough current assets to cover current liabilities, as shown by its current ratio of 1.17.
The Market May Be Undervaluing Pfizer's Assets and Equity:
PFIZER INC has a trailing twelve month P/E ratio of 14.6, compared to an average of 22.94 for the Health Care sector. Based on its EPS guidance of $2.99, the company has a forward P/E ratio of 8.4. The 0.8% compound average growth rate of PFIZER INC's historical and projected earnings per share yields a PEG ratio of 17.83. This suggests that these shares are overvalued. In contrast, the market is likely undervaluing PFIZER INC in terms of its equity because its P/B ratio is 1.54 while the sector average is 3.19. The company's shares are currently trading 13.3% below their Graham number.
Pfizer Has an Analyst Consensus of Some Upside Potential:
The 24 analysts following PFIZER INC have set target prices ranging from $24.0 to $36.16 per share, for an average of $28.87 with a buy rating.
PFIZER INC has an average amount of shares sold short because 2.5% of the company's shares are sold short. Institutions own 67.5% of the company's shares, and the insider ownership rate stands at 0.08%, suggesting a small amount of insider investors. The largest shareholder is Vanguard Group Inc, whose 9% stake in the company is worth $13,413,978,332.
